RESEARCH – The laboratory announced on Tuesday that the treatment against the coronavirus it is currently developing has not proven its effectiveness on people exposed to the virus. The tests will however continue.
LCI editorial staff – 2021-06-15T12:25:37.264+02:00
Another setback for AstraZeneca. After many countries have partially or totally turned away from its anti-covid vaccine, the Anglo-Swedish pharmaceutical group announced on Tuesday that the treatment against the coronavirus that it is currently developing has not proven its effectiveness on exposed people to the virus.
“The trial did not achieve the main goal of preventing symptomatic Covid-19 cases after exposure” virus, explains AstraZeneca in a statement.
All the info on
Coronavirus: the pandemic shaking up the planet
A reduction in symptoms of only 33%
Antibody therapy, codenamed AZD7442, was expected to both prevent and treat the disease. It was in phase 3 of development, that is to say in large-scale clinical trials in order to measure its safety and effectiveness.
The 1,121 participants were adults over the age of 18 who were not vaccinated and who had been exposed to an infected person within the previous eight days. The treatment only reduced the risk of developing Covid-19 with symptoms by 33%. Trials are continuing to evaluate the remedy in patients before exposure to the virus, and for those who have developed severe forms.
The important investment of the United States
The development of this treatment is funded by the US government, which in turn had signed agreements with AstraZeneca to receive up to 700,000 doses this year. In total, the value of the agreements with the United States for the development of the treatment and the doses in 2021 reaches 726 million dollars.
In its press release, AstraZeneca indicates that discussions are underway “regarding next steps with the US government”.
If hopes vis-à-vis the treatment developed by AstraZeneca are showered, all eyes are now on the Institut Pasteur de Lille. It has just obtained the green light from the National Medicines Safety Agency to test a treatment with suppositories against Covid-19 on patients. In October, the Institute announced that it had received a donation of five million euros from the luxury giant LVMH to finance the clinical trial of a molecule which, tested in vitro, turned out “particularly effective against the SARS-Cov-2 virus”.
On the same subject
The most read articles
England: overtaken by the Delta variant, Boris Johnson shifts deconfinement by one month
LIVE – Anti-covid vaccine: Doctolib announces 62,000 appointments made for people under 18
What is happening at the Taishan nuclear power plant in China?
“It’s going to be yellow vests power 10”: the sling of motorists against EPZs in the city center
Bac: graduated at 13 in 2015, what becomes of Pierre-Antoine?
defends the ambition of information
verified and accessible to all thanks to the income of the
To help us maintain this free service you can “change your choice” and accept all cookies.
MODIFY AND ACCEPT ALL